Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: a 171-patient series
- 14 May 2010
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 100 (3) , 417-426
- https://doi.org/10.1007/s11060-010-0193-x
Abstract
In the last few years much has been published to validate new technology in brain mapping for clinical purposes, but there have been few clinical results. In this report we describe our five-year experience in the surgical management of malignant gliomas around motor areas with an evaluation of the impact of functional magnetic resonance imaging (fMRI) plus navigator and intraoperative neurophysiology (IN). End-points were extent of removal, morbidity, and survival. Variables describing patient and tumor characteristics and treatment modalities were statistically weighted in relation to treatment outcome. Tumor depth (P = 0.01), midline shift ≥1 cm. (P = 0.05), and insular location (P = 0.001) negatively affected extent of removal, whereas IN (P < 0.001) and fMRI plus navigator (P = 0.02) contributed to increasing the rate of total removal (73%, 71% vs. 40%). Postoperative motor impairment was mild and transient in a minority of cases (20%). General complications, as defined by the Glioma Outcome Project, occurred in 23% of cases. IN was the only factor associated with acute postoperative motor deterioration (P < 0.001). IN and age >65 years (P = 0.01) were associated with the occurrence of complications. Overall survival was significantly higher in patients operated with IN or fMRI plus navigator (P < 0.01). Comparing different surgical strategies used in the same period, we observed that supportive technologies in glioma surgery have their primary impact on the quality of resection and survival. IN led to transient motor impairment and some additional complications which did not affect functional outcome.Keywords
This publication has 45 references indexed in Scilit:
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Recent developments in the use of chemotherapy in brain tumoursEuropean Journal Of Cancer, 2006
- Resection of parietal lobe gliomas: incidence and evolution of neurological deficits in 28 consecutive patients correlated to the location and morphological characteristics of the tumorJournal of Neurosurgery, 2005
- Neuronavigation Combined with Electrophysiological Monitoring for Surgery of Lesions in Eloquent Brain Areas in 42 Cases: A Retrospective Comparison of the Neurological Outcome and the Quality of Resection with a Control Group with Similar Lesionsmin - Minimally Invasive Neurosurgery, 2003
- Neuronavigation and Functional MRI for Surgery in Patients with Lesion in Eloquent Brain Areasmin - Minimally Invasive Neurosurgery, 2002
- Awake Craniotomy for Aggressive Resection of Primary Gliomas Located in Eloquent BrainMayo Clinic Proceedings, 2001
- Functional Cortex and Subcortical White Matter Located within GliomasNeurosurgery, 1996
- The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- Serial Stereotactic Biopsies: a Double Histological Code of Gliomas according to Malignancy and 3-D Configuration, as an Aid to Therapeutic Decision and Assessment of ResultsStereotactic and Functional Neurosurgery, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958